1INTRODUCTIONCytoreductive surgery (CRS), along with hyperthermic intraperitoneal chemotherapy (HIPEC) has been gaining acceptance as the treatment of choice for selected patients with peritoneal metastases (PM) from gastrointestinal, ovarian and peritoneal origins. In a prospective study of 460 patients with PM from gastrointestinal malignancy, who underwent 501 (CRS‐HIPEC) procedures, the median survival was found to be 22.2 months with a 5‐year survival rate up to 27.8%. This exceeds the median survival of approximately 6 months for patients with PM who are treated with systemic chemotherapy or conservative management with a palliative intent.With higher life expectancy in an increasingly aging population, we can expect an increasing number of elderly patients, i.e. aged 65 and above as well. However, physicians may be less likely to consider CRS and HIPEC for elderly patients because of the presumed higher morbidity associated with age. There have been studies looking at the morbidity and mortality associated with CRS and HIPEC, but none are focused on elderly patients, with limited literature on CRS and HIPEC in the elderly population.Using prospectively collected data from a tertiary institution, we examined the outcomes of elderly patients who underwent CRS and HIPEC for PM from ovarian, colorectal and other gastrointestinal cancers,
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera